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Summary An increasing number of reports highlight the fact that tumour cells are able to give rise in vitro
to immunogenic variants, which are defined in vivo as being non tumorigenic, tum-. We have observed the
emergence of immunogenic variants, derived from a primary nickel-induced rat rhabdomyosarcoma
established in culture (RMS 9-4/0), resistant to treatment with the chloronitrosourea, chlorozotocin (CZT) (R-
lines). They were separated from the whole population of cells by a cloning procedure. Furthermore, we
demonstrate that the cloning procedure by itself allows the isolation of tum- variant designated as C-lines.
In both cases, the tum- phenotype was observed after s.c. injection of cells into syngeneic rats with a broad
range of R9 or C8 cells (104 to 107). This characteristic was inherited in a stable manner. Athymic mice
developed tumours of rat rhabdomyosarcoma origin when grafted with 105 cells. Immunization of rats with
one R variant (R9) tum- protected the rats grafted with the parental RMS 9-4/0 cells against metastatic
invasion of the lungs, but not against local tumour growth, and rats grafted with a CZT-resistant tum+ cell
variant S4T (in vivo-derived) against its hepatic and pulmonary metastases, while the local tumour progressed
as usual. Immunization of rats with one C variant (C8) tum- cells did not protect them against either
metastases or local growth of the implanted tumours. Both R and C lines cells became progressively resistant
to NK- and macrophage-induced cytotoxicity. Splenic lymphocyte transfer from immune rats into nude mice,
i.e., the Winn test, showed a complete degree of protection against C8 or R9 tumour growth.
We conclude that two different antigenicities were revealed, one common to R9 and C8 cells in relation
with their selection procedure by repeated cloning. Another antigenicity appeared in the R9 line, selected by
CZT-resistance. The anti R9 cell immunization against CZT-resistant tum+ S4T could argue in favour of
CZT action in the acquisition of R9 cell antigenicity. More likely, an amplification of antigens rather than
induction of a new antigen could explain the protection of anti R9 immunized rats against parental tumour
metastases.
Induction of tumour cell antigenicity as a consequence of been demonstrated, see e.g. Evans, 1986) or if the tumour
their treatment by drugs has already been demonstrated by cells present the epitopes in an inefficient way to the immune
several authors (Fioretti et al., 1983; Nardelli et al., 1984; system (loss of expression of major histocompatibility
Boon & Kellerman, 1977). Circumstances under which such complex antigens, for example).
observations have been made differed. For example, Van Pel More and more authors have reported that tumour cells
and Boon, (1983) showed that MNNG and other mutagenic are able to give rise to new variants, especially non-
drugs were able to induce in tumour cells a high level of tumorigenic variants, obviously obtained in vitro in the
variants able to protect mice against primary leukaemia. absence of the immune pressure exerted in vivo by the host,
Interestingly, they demonstrated that some of them were not as reported by Price (Price et al., 1986). Spontaneous or
tumorigenic when reinjected into syngeneic animals, thus drug-induced mutations could be responsible for this effect.
defining the term tum- (Boon, 1985). Injected into Technically, the cloning procedure preceding the selection of
immunoincompetent animals, the same cells were the sublines is absolutely necessary, in order to demonstrate
tumorigenic, indicating that the lack of tumorigenicity in the emergence of these immunogenic variants. Without
normal animals was due to the immunological rejection of cloning, the immunogenic variants are diluted in a broad
the variants. In their subsequent papers, Boon et al. (see population of cells and they are killed when injected into
Boon, 1985 for review) defined the nature of the immune immunocompetent animals.
rejection and the specificity of various epitopes. Some clones In our studies, we have observed that some lines, selected
shared an antigenicity expressed by the parental cells (not from tumour cells derived from a nickel-induced rhabdomyo-
mutated), while others presented specificities differing from sarcoma by repeated contact with chlorozotocin (CZT)
the parental cells and specific to each clone. The common followed by cloning, became non-tumorigenic when injected
antigenicity shared by parental cells and mutated variants into syngeneic immunocompetent rats. This complicated and
was first demonstrated by the rejection of parental tumour long-term procedure was applied to obtain progressively
cells when injected into animals immunized by tum- cloned CZT resistant-cells from the clonogenic subpopulation of
cell lines. It is interesting to note that parental cells by tumour cells. Grafting of the same CZT-resistant cells into
themselves were unable to immunize the animals, whereas nude rats led to tumour proliferation, indicating the
animals previously immunized with tum- cells could immunological nature of the tumour cell rejection in normal
perfectly recognize the non-immunogenic parental cells and animals. The role of repeated cloning procedures in the loss
destroy them. Specific antigenic structures could be carried of tumorigenicity of selected cell lines was evidenced.
by parental tumour cells without inducing tumour cell However, we proved that CZT treatment of the cells, in
rejection. The absence of immunological rejection of tumour addition to the cloning procedure, coincided with the
cells is the rule, and the tumour cell graft takes in the emergence of a new variant, which expressed acquired or
recipients and grows. This has been the basis of many amplified immunizing structures, also present on metastatic
studies attempting to define if the tumour-bearing hosts are tumour cells. The common features of antigenic structures
deficient in their recognition (the role of suppressor cells has borne by stem cells, isolated in vitro by nitrosourea-resistance
and cloning, and metastatic cells re-inforce the hypothesis of
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Materials and methods Syngeneic female (8 week old) athymic rats, descendants
of the MRC (UK) line were bred in our laboratory. Rats
Animals received 1 x 106 CZT-R9 cells by s.c. injection into the flank.
All rats developed tumours. When the tumours reached
Inbred Wistar AG female rats 8-12 weeks old were obtained 15mmti diameter, tumourtsewas tically rested
from~~~~~~~ th pcfcptoe-rebedn aiiyo h 15mm in diameter, tumour tissue was aseptically harvested, from the specific pathogen-free breeding faclity of the cut into very small pieces and placed under the usual culture
Institut de Recherches Scientifiques sur le Cancer. mdu odtos fe eea as ueostmu
Nude rats with a Wistar AG genetic background were cells, podutsoof te r fragments, prolfrtedoan
obtained from the MRC (UK) at the 10th backcross. They cells, products of the tumour fragments, proliferated and obtairedfromthe MRC(UK)atthe10th backcross.andth y Trey u formed a cell monolayer. The reinjection of these cells into
were bred to the 12th back(cross and the progeny were used ne sygei atyivitrA as nue h rwho
in these experiments. ~~~~new syngenic athymic Wistar AG rats induced the growth of
a new tumour, proving their tumorigenicity. Histological
analysis confirmed the striated muscle tissue origin of the
Reagentstuor tumour.
Chlorozotocin (2-(3-(2-chloroethyl)-3 nitrosoureido)-D-gluco- Metastatic ability (meta+) was estimated in rats which
pyranose); CAS: 54749-90-5), a nitrosourea and alkylating had received the tumour cell grafts by s.c. route and which
agent, was provided by the Division of Cancer Treatment, developed a local tumour. Metastases developed in the lungs
National Cancer Institute, Bethesda, MD. Diluted at a con- and lymph nodes. Rats were killed when moribund (2-3
centration of 1 mgml-1, it was stored at -20°C until use. month evolution time), and the number of tumour nodules
was counted at the surface of the lungs. Lymph nodes were
Cell lines and establishment ofvariant cell lines examined and tumour invasion was noted. The malignant
nature of tumour nodules was confirmed by histological
RMS 9-4/0 parental cells were derived from a primary examination.
nickel-induced tumour in a Wistar AG inbred rat, as
previously described (Sweeney et al., 1982). Cells and Cytotoxicity assay with macrophages and NK lymphocytes
resistant variants were maintained in Dulbecco's modified
Eagle's medium (DMEM, H21, Grand Island Biological Co. Macrophages were harvested by repeated washes, with 40ml
Glasgow, UK) supplemented with 10% heat-inactivated of 0.2% EDTA in PBS, of the bronchoalveolar area of
foetal calf serum (FCS) and subcultured twice weekly by previously healthy rats killed by an overdose of nembutal
trypsinization. Cells were used between the 15th and 30th in (barbituric suspension). Alveolar macrophages were centri-
vitro passages and a stock was kept in liquid nitrogen. Cells fuged and then suspended in HAM medium (Grand Island
were always free of mycoplasma contamination, as assessed Biological Co., Glasgow, UK) supplemented with 5% endo-
by Hoechst staining (Chen, 1977). free FCS (from Flow Laboratories, UK), counted and
Chlorozotocin-resistant variants were selected from the distributed into the wells of microplates at concentrations of
RMS 9-4/0 parental line by repeated exposure to CZT using 1.25, 2.5, 5 and 10 x 104 cells per well in 0.1 ml of 5%
the following procedure. Cells in log-phase growth mono- endofree FCS-HAM medium.
layers were detached by a 0.25% trypsin/PBS solution, put Tumour cells were pre-labelled with [14C]-inosine (specific
into tubes in the presence of serum, washed once, adjusted activity 40-60mCimmol- 1; Amersham, UK). Briefly, 1 x 106
to 106ml-1, exposed to 0.4,gml-I ofjust thawed CZT, and cells were seeded in a 10cm Falcon petri dish in 10ml of
kept at 37°C for 1 h. Then, treated cells were washed twice, standard culture medium; 0.1 I Ci of [I4C]-inosine was added
suspended in 0.3% Bacto-agar (Difco Lab, Detroit, MI), to the medium and the mixture was incubated overnight in
kept fluid at 37°C in a water bath, then deposited onto a a 5% C02/air incubator at 37°C. Labelled tumour cell
gelled 0.6% agar layer, previously prepared. After 1 week of monolayers were extensively washed with PBS, trypsinized,
incubation at 37°C in a humidified atmosphere of 5% CO2 suspended in 5% endofree FCS-HAM medium, counted and
in air, colonies of resistant cells were harvested with a adjusted to a concentration of 1 x 105 cellsml-1. This
syringe under a microscope and each colony was seeded in suspension (0.1 ml) was added to each well. To activate
a 35mm Falcon petri dish according to the liquid medium macrophages, 30% of the culture medium was replaced by
culture conditions described above. From each colony, a cell MAF (macrophage-activating factor). Briefly, to prepare
line was expanded as a monolayer: lines were called R lines. MAF, lymphocytes were isolated from the spleens of
These cells were then subjected to a new CZT treatment cycle. syngeneic rats, washed twice, incubated for 4h in a 10%
In the present investigation, the CZT-resistant cells were endofree FCS-HAM medium containing 2,ugml- of
identified by the number of CZT treatment cycles they had concanavalin A (Con A), 5 x 106 lymphocytesml-. After a
undergone. At each treatment cycle, part of the cells were 4h incubation at 37°C, 5% CO29 the medium was replaced
kept, subcultured and stored in liquid nitrogen. by the same medium without Con A. After a total period of
The same cloning procedure except for the CZT-treatment 48h, the cells were discarded and the supernatant, designated
was used to obtain C lines. The parental line was cloned as MAF, was passed through a 0.22,um Millipore filter and
after a 1 h incubation in drug-free medium. From one stored at 4°C until use.
colony, a cell line was obtained and this cycle was repeated. Macrophages and tumour cells were mixed together in the
These reference lines were identified by the number of presence or absence of MAF, with three identical aliquots
cloning cycles. per experiment, for 72h in a 37°C humidified 5% C02/air
S4T lines were in vivo resistant cell lines: rats bearing RMS incubator. Then, 0.1 ml (halt) of the supernatant from each
9-4/0 were treated with CZT (10mgkg-1). Local tumours well was collected, mixed with 1 ml of scintillation liquid
were dissected when rats were moribund and grafted s.c. into (Aqualuma; Kontron Analytique, Monsigny le Br., France)
a new series of syngenic rats. These rats were treated with and counted in a beta counter. The radioactivity released
CZT according to the same protocols. Five in vivo passages represented the radioactive cells killed by macrophages.
and treatments were necessary to obtain S4T lines. These Lymphocytes comprising natural killer (NK) cells were
lines were more tumorigenic and metastatic than RMS 9-4/0. dissociated from the spleens of healthy rats. After spinning
at low speed to eliminate a large number of red blood cells,
Evaluation oftumorigenic and metastatic potentials the lymphocytes were counted and adjusted to concen-
trations of 20, 10, 5 and 2.5 x 106ml-i of 10% FCS-DME
Tumorigenic activity turn + was estimated by the injection medium. Tumour cells were labelled with 200 ,uCi of sodium
of 5x 106 cells s.c. into 8 week old Wistar AG rats. It was 51Cr-chromate (Amersham, UK) added to 2x 106 tumour
concluded that a given line was non tumorigenic (tum-) if cells in a volume of 0.2ml of complete medium for 2h at
repeated injections did not result in tumours by 12 months 37°C. After extensive washing, labelled tumour cells were
afterthelasttumourcellgraft. suspended at 105 cellsml 1. One hundred ,ul of eachTUM-CFCs FROM A RAT RHABDOMYOSARCOMA 9
suspension were mixed in wells of a 96-well Falcon micro- selected cells. The R lines were selected after 1 h of contact
plate. After 5 h of incubation, 0.1ml of each suspension was with CZT, immediately followed by cloning in soft agar,
measured for radioactivity in a gamma counter. growth and subsequent passage into liquid medium culture
For both cytotoxic assays, total radioactivity was liberated conditions. R lines were defined by their resistance (R) to
in the presence of 0.1 ml of 1 M HCl which replaced the this drug and their clonogenicity. The C-lines were
effector cell suspension. Spontaneous release was measured repeatedly cloned, but not treated with CZT. At different
in wells where effectors were replaced by complete medium steps of the in vitro selection procedure, the sublines were
alone. Three identical samples were run for each analyzed for expression of the two phenotypes: tumori-
combination. genicity tum+ and metastatic capacity meta+. All R lines
% cytoxicity was calculated as: remained tum+ and meta+ until the 6th exposure to the
drug. The same observation was made for the C lines until
100-100 x cpm in test - cpm spontaneous release the 8th cloning (Table I).
cpm total labelling - cpm spontaneous release
Table I Tumorigenic properties of cell lines
Rat immunization established from primary tumour RMS 9-
Groups of 10 syngeneic rats, 10 weeks old, were immunized 4/0 and cloned cells derived fromit with (R)
with 107 RMS 9-4/0 cells, 100Gy irradiated, injected i.p. or without (C) pre-cloning treatment with
weekly for 6 weeks. Other groups of 10 syngeneic Wistar AG 0.4igml- of CZT
rats of the same age received 107 R9 or C8 cultured cells Tumour take in recipient
tum -, i.p., weekly for 6 weeks. One week after the last Wistar AG rats
immunizing injection, 105 viable RMS 9-4/0 or S4T from
subconfluent cultures were grafted s.c. Upon the appearance Injected
of a tumour at the injection site, its growth was individually cells Normal Athymic nude
measured weekly with a caliper. When rats presented RMS
respiratory distress, they were killed and tumour nodules 9R4/0 104a 5/5b 5/5b
were checked in the lungs and lymph nodes at autopsy. 105 5/5 5/5
Healthy rats were killed at the same time as the last 106 5/5 -
moribund rats. l07 5/5
R5 104 2/10 -
Winn test in nude mice 105 8/10 5/5
106 10/10 5/5 Groups of 5, 6 week old female, genetically athymic mice, 107 10/10 -
from IFFA-Credo breeding facilities (Lyon, France),
received s.c. 0.2ml of MEM medium containing a mixture of 105 0/10 5/5
T lymphocytes and R9 or C8 tumour cells according to the 106 0/10 5/5
Winn assay (Winn, 1961). Briefly, lymphocytes were 107 0/10 -
prepared from the spleens of Wistar AG rats, non- 4 104 8/10 -
immunized or immunized against R9 or C8 cells as described 105 10/10 5/5
above. Spleens were aseptically removed, dissociated, filtered 106 10/10 -
through a stainless steel sieve, and washed in MEM. To 107 -
separate the T cell-enriched populations, 108 total spleen C8 104 - -
cells in 2ml of MEM plus 10% FCS were placed on a 0.3g 105 0/10 5/5
column of nylon wool (LP-1 leukopak leukocyte filter; 106 0/10 5/5
Fenwal Lab., Morton Grove, IL) incubated for 30min at 107 0/10 -
37°C and rinsed with 15ml of MEM 10% FCS at 37°C. T
enriched spleen cells, 50 x 106, were mixed with 1 x 106 R9 or aNo. cells injected s.c. into each rat; bNo.
C8 tumour cells in a total volume of 0.2ml. Controls were rats developing primary tumours at the in-
normal T cells instead of immune T cells, administered at the jection site out of the total number of rats
same T cell: tumour cell ratio, and tumour cells injected receiving tumour cells.
alone. Mice were checked twice weekly. The day of tumour
appearance was noted and its growth rate was monitored for The in vivo behaviour of RMS 9-4/0, C5, R3 lines, was 45 days. influenced by chlorozotocin given to tumour bearing rats
Statistical anal sis weekly, at the dose of 10mgkg-I (Table II). As previously
described (Poupon et al., 1984; Pauwels et al., 1985) CZT
The statistical significance of differences in cloning efficiency enhanced the metastatic potential of RMS 9-4/0 tumours,
(CE) or proliferation was analyzed using the Student's t-test. and slowed the growth rate of the primary tumour. This is
The median number of lung metastatic nodules was observed when C5 tumour bearing rats were treated. The
calculated and the statistical significance was evaluated by growth rate of R-tumours (R3 and R6) was unchanged
the non-parametric Wilcoxon test. under CZT treatment, while their metastases were identically
enhanced. In vivo, when RMS 9-4/0, C5, R3 and R6 were
Results injected s.c. to induce local tumours, we observed spontaneous dissemination of tumour cells to the lungs
. . ~~~~~(Table 11) as well as to the lymph nodes. These lines did not
Tumrigeni obainedfrmetsai
chrctrstc of-hetun0 differ significantly from one another and they formed variantsobtained from RMS 9-4/0growing tumours.
Subcutaneous injection of 105 viable RMS 9-4/0 cells into From one R6 colony, expanded as a monolayer, we
Wistar AG rats was followed by the local growth of a derived four R6 lines from four independent colonies: they
tumour, histologically characterized as a differentiated were all tumorigenic and metastatic in syngeneic rats. The
rhabdomyosarcoma. After development of the local tumour, four R7 lines derived from independent colonies were found
metastases formed in the lymph nodes and then in the lungs, to be non tumorigenic under the same conditions. The same
causing the death of animals within 90-100 days. From the observation was made for the C lines after the 7th cycle of
RMS 9-4/0 cells, we have obtained two types of in vitro treatment. In all cases, in spite of repeated cell injections,10 C. PAUWELS-VERGELY & M.-F. POUPON
Table II Effect of CZT on tumorigenicity and meta- Effects ofimmunization ofrats with irradiated RMS 9-4/0
static abilities of selected variants cells, R9 or C8 cells upon growth and metastatic spread of
RMS 9-4/0 or S4T grafted tumours
Grafted Tumour size Median number
cells CZT- at autopsy oflung tumour The RMS 9-4/0 cell line has been previously shown to be
(105 per rat) treated (mm+s.d.) nodules (range) poorly immunogenic (Pot-Deprun et al., 1983). Six weekly
injections of 100Gy irradiated tumour cells with as many
RMS 9-4/0 - 38+3 10 (0 4) as l07 cells per injection before RMS 9-4/0 challenge +d 27+2 105 (29-118)C significantly decreased tumour growth but not the metastatic
C5 _ 32+2 19 (2-36) potency of the tumour implanted in immunized rats (Table
+ 27+2b llOC (35-145) III). R9 (107 cells) was injected i.p., weekly for 6 weeks, into
R3 - 43+8 7 (1-10) immunocompetent syngeneic rats in order to immunize them.
+ 41+9a 87c (65-114) The results of subsequent injections of viable RMS 9-4/0
R6 - 35+4 5 (2-10) cells are reported in Table III. Tumour growth was only
+ 33+4~- 94C (52123) slightly retarded by R9 immunization, but the number of
lung tumour nodules significantly decreased (median number
Ten rats per group. 4 versus 22; P<0.01).
aStatistical differences not significant; bP<0.02; Another group of rats immunized against R9 cells received
CP<0.01. Statistical differences in mean tumour sizes S4T tumour cells selected in vivo for CZT resistance
were calculated using the Student's t-test. For meta- (submitted for publication). The anti-R9 cell immunization
static counts, the non-parametric Wilcoxon test (Siegler) protected the rats against the pulmonary dissemination and
was used; dChlorozotocin was given i.p. weekly for 3 also against liver metastases. This S4T cell line was previously
weeks at the dose of 10mgkg-' body wt. The first characterized by its very high metastatic potential, rapidly injections were given when the primary tumours invading the lungs, the lymph nodes and the liver, after
measured 10mm diam.
development of a s.c. primary tumour.
The results suggest the appearance of a newly expressed
structure on R9 cells which enables the competent host to
and an increase in the number of cells injected to I0 per rat recognize and reject them. The fact that immunization
and several months of observation (12 months), no tumours against R9 cells decreased lung metastatic invasion and
appeared. Tumorigenicity seemed to be definitively lost, since stopped liver metastases without affecting primary tumour
the subsequent clones R7, R8, R9, C8 and C9 were not growth suggests that identical epitopes are present on these
tumorigenic. CZT-resistant clonogenic cells and on potentially metastatic
We also attempted to induce tumorigenicity by treating R9 cells.
tum- cells with CZT before s.c. injection, but had no Immunization of syngeneic immunocompetent rats with
success. C8 cells did not protect them against metastatic invasion of
All of the immunodeficient rats, either nude rats on the the lungs after a s.c. graft of RMS 9-4/0 tumour cells (Table
Wistar AG genetic background or newborn Wistar AG rats, III). Compared with the immunizing potential of R9 cells,
developed tumours when injected with 106 or 105 R9 cells or C8 cells, although not tumorigenic in syngeneic hosts, did
C8 cells. Metastatic potential was generally co-expressed not show any shared antigenicity with the parental cells,
with tumorigenic potential, except in Wistar AG nude metastatic or not.
recipients where no metastases occurred. Many of our
experiments, including these, have shown that nude animals Interactions between immunocompetent cells and selected
very rarely develop tumour metastases even when, in similar variants
experiments, the metastatic potential of the injected cells can
be simultaneously controlled in immunocompetent animals. During the selection process, the loss of tumorigenicity by
The apparent loss of tumorigenicity by R9 cells and C8 the variants could be related to a higher sensitivity to the
cells in immunocompetent animals could be related to their immune system, namely to NK cells or macrophages,
acquisition of antigenicity, thus provoking their rejection by activated or not. Indeed, if membrane changes render them
normal hosts but not by immunoincompetent Wistar AG highly sensitive to killing, this could explain the results
hosts. We have further analysed the immunogenicity of two observed and the absence of tumorigenicity. As shown in
selected lines, R9 repeatedly treated with CZT, and C8 not Table IV, the RMS 9-4/0 line is relatively sensitive to NK
treated, both selected by the cloning procedure. lysis (29.4% at the 100:1 lymphocyte/tumour cell ratio).
Table III Immunization of normal Wistar AG rats with R9 clonogenic resistant
cloned cells, C8 clonogenic cloned cells and irradiated RMS 9-4/0 cells
Median no.
Tumour size No. rats lung No. rats
Grafted Immunizing diameter with lung tumour nodules with hepatic
tumour cells mm+s.d. metastases (range) nodules
RMS9-4/0 - 38.5+2.5 10/10 22 (2-49) 0
IrradiatedC
RMS9-4/0 28.4+5.6 10/10 25 (4460)a 0
R9 34.5+ 1.5 8/10 4 (0-14)" 0
C8 38.6+ 10 10/10 19 (2-72)a 0
S4T - 36.8+i4 10/10 109 (64-170) 6/10
R9 32.7+3 10/10 18 (2-53) 0
aStatistical differences not significant; "p<0.05. Statistical differences were calcu-
lated using the non-parametric Wilcoxon's test; CI 00Gy given in 1 h.TUM-CFCs FROM A RAT RHABDOMYOSARCOMA 11
Table IV Sensitivity of a CZT-resistant selected
line to natural killer splenic lymphocytes as com-
pared to parental sensitivity
80
Lines and Regression
cell variants % lysis Slope index
*Z 60-. / ,' RMS 9-4/0 29.4 0.25 0.99 x 60
RI 29.4 0.26 0.99 ° 0 R3 18.6 0.13 0.97 °,_
R6 7.8 0.09 0.98 U 40,
R7 11.3 0.13 0.99 I ,-
R9 6.7 0.08 0.97
R10a 1 6.3 0.06 0.99 20
2 5.4 0.04 0.96 20
3 10.5 0.1 0.99
4 6.8 0.07 0.99
5 8.0 0.07 0.95
6 8.6 0.06 0.93 1.1 3:1 9 1
7 6.2 0.05 0.96 Macrophages Cells
8 3.7 0.03 0.98 Figure 1 Macrophage activity against tum+ R3 (@,0) and
914.1 0.12 0.99 tum- R9 (-, l). Macrophages were activated (solid symbols) or
The cytotoxicity assay was performed, as de- not (open symbols) by MAF or nocardia extract.
scribed in Materials and methods. Briefly, 51Cr-
labelled tumour cells in the appropriate medium Adoption oftumour immunity in nude mice
were mixed with splenic white cells containing
NK lymphocytes at the ratios of 1 to 200, 100, 50 In genetically athymic nude mice, R9 and C8 cells gave rise
or 25. After 5h of incubation, supernatant ali- to tumour proliferation in one week, when I x 106 cells were
quots were counted in a gamma counter. The injected s.c. When 50 x 106 T enriched spleen cells from non-
radioactivity released was proportional to the immunized rats were mixed with R9 or C8 tumour cells,
labelled cell lysis. % cytotoxicity was calculated tumour appearance was delayed 6 days, however all the mice
for each lymphocyte-to-tumour cell ratio and the eventually developed tumours (Table V). If T enriched spleen
results were analyzed by a computer. The cell cells were obtained from rats immunized against R9 or C8
ratio to % cytotoxicity slope was calculated as . .
well as the regression index which validated the u
linear relationship between cytotoxicity and the mice, over the 3 month observation time. Moreover,
cell ratio. The % lysis for the ratio 100:1 was immunization against R9 protected against C8 tumour take,
deduced from these linear curves. and vice versa. These results demonstrate that rats developed
aRIO clones were derived from the R9 subline. immunity against R9 and C8 tumour cells, that T cells were
Nine clones were independently harvested and responsible for their rejection and that C8 and R9 shared
expanded as sublines. Each was assayed in the common antigenic structures.
cytotoxicity test.
Table V Effect of addition of T enriched
Calculations of the slope of the curve indicate the degree of spleen cells obtained from normal or immu-
dose-dependency between cytotoxicity and the nized rats on the protection of genetically athy-
lymphocyte/tumour cell ratio. The regression index has to be mic nude mice against R9 or C8 tumour take
as close to unity as possible. We observed that progressive
resistance of cells to NK lysis developed with selection. Origin ofTenriched Injected Tumour
Finally, R9 cells appeared to be highly resistant. A series of spleen cells cells take
9 clones derived from R9 showed no exceptions: all clones Normal rats C8 4/4
were NK-resistant to varying degrees. R9 5/5
Macrophages are also capable of killing implanted tumour
cells without prior immunization. We compared the killing against R9 R9 0/5
by non-activated or MAF-activated macrophages in an in
vitro assay. As detailed in Materials and methods, [14C]- Rats immunized C8 0/2
labelled tumour cells were added to bronchoalveolar against C8 R9 0/5
macrophages, already attached to the bottom of 96-well
Falcon microplates, and MAF was added to the culture
medium (1:3, v/v). After a 72h incubation, the supernatants Discussion
containing the radioactivity released by killed cells were
harvested and counted. Figure 1 compares the macrophage The procedure of drug contact followed by cloning in semi-
activity against R3 tum + and R9 tum - cells. R9 appeared solid agar designated as the Salmon assay (Salmon et al.,
to be strongly resistant to lysis, even when macrophages 1978) has been used by 'many experimenters in order to
were activated. Macrophage activation was confirmed by evaluate the sensitivity of stem cells to the cytotoxicity of
their increased cytotoxicity against R3 cells. The turn- chemotherapeutic drugs. We have used this procedure to
phenotype of R9 and C8 cells could not be explained by select cell variants resistant to the nitrosourea, CZT. To
enhanced cytotoxicity of these two immune system effectors. reinforce cell selection, we repeated this procedure nine
We have also tried to provoke specific cytotoxicity times. Similar procedures which consist of repeating drug
mediated by T lymphocytes from rats immunized against R9 contacts with the tumour cells were often used with different
or C8 cells, either as a direct assay or after a four day drugs, leading to the isolation of drug-resistant variants. For
stimulation of lymphocytes in the presence of irradiated R9 example, Giavazzi et a!. (1983), among others, have obtained
or C8 tumour cells. The results are not shown since they adriamycin-resistant cells from a murine fibrosarcoma, by
revealed no cytotoxicity. adding progressively increasing doses of adriamycin to the
In order to demonstrate the role of immunity in the R9 or cell culture medium. The originality of our study lies in the
C8 rejection by immunocompetent Wistar AG rats, we used fact that we have chosen to select clonogenic and chemo-
the Winn assay. resistant cells, using a protocol which associated the usual12 C. PAUWELS-VERGELY & M.-F. POUPON
procedure of repeated drug contact with post contact mediated by T cell dependent cytolysis, others inducing a T
cloning. This procedure was capable of progressively helper mediated mechanism. Their more surprising obser-
increasing the frequency of clonogenic drug-resistant cells vation is that the most malignant line (metastatic) which
(selective procedure), or increasing the drug resistance of arose spontaneously under immune pressure, induced an
individual clonogenic cells (adaptative mechanism, Laval, immune state in mice, allowing them to reject the graft of
1985). The observation of phenotypic changes in the tumour the parental tumour but not their own graft. This study
cells derived from our sarcoma, after treatment by CZT, clearly showed that this highly malignant tumour also
could explain two previous observations. Firstly, rats grafted expressed antigenic determinants. The induction of anti-
with the RMS 9-4/0 tumour, and subsequently treated by genicity on tumour cells by drugs has already been demon-
CZT developed a greater number of lung metastases than strated. Boon, (1985) has shown that N-methyl-N'-nitro-N-
nontreated rats. Secondly, in vitro contact of RMS 9-4/0 cells nitrosoguanidine (MNNG) and other mutagens are capable
with CZT, increased their cloning efficiency, i.e. induced of inducing a high level of mutants in tumour cells and that
some tumour cell to express de novo a clonogenic efficiency. many of them carry antigenic structures. Some of them are
This in vitro procedure for the selection of tumour cell similar to structures present on the parental non-mutated
variants, by a selective or adaptive mechanism, could lead to cells, whereas others are specific to each clone. The nature of
the isolation of highly metastatic and drug resistant variants. these structures has not been elucidated, but a tissue-specific
However, it excludes the selective pressure exerted by the structure determined by the tissue origin of the tumour
host. during embryogenesis is one good candidate (Fidler &
We report here that the cloning procedure by itself gave Nicholson 1976; Frost & Kerbel 1983). Along the same line
rise to tum- variants. Two types of tum- variants were of thought, Nardelli has indicated that in murine lymphoma
obtained. The R lines after CZT-contact; the C lines without cells repeated treatment with drugs in vitro generated highly
drug contact. These two types of clonogenic cells, colony immunogenic sublines (Nardelli et al., 1984). A similar effect
forming cells (CFCs), were shown to be immunogenic in was observed after UV irradiation, which was followed by
Wistar AG rats, and tumour cell rejection could be affected cell changes and the appearance of antigenic structures
by T cells, as was demonstrated by the transfer of immunity (Kripke et al., 1978). A hypomethylating drug such as 5-
to nude mice by T lymphocytes from immunized rats. azacytidine was able to provoke similar changes in tumour
Moreover, when CZT-resistant CFCs were used to immunize cells. Moreover, Olsson & Forchhammer (1984)
syngeneic recipients, they were able to protect the hosts demonstrated that expression of a particular antigen is
against metastatic dissemination of the parental cell line, s.c. closely associated with the metastatic potential of tumour
grafted and growing as a malignant primary tumour. This cells of the 3LL adenocarcinoma of C57BL/6 mice. Re-
surprising observation was confirmed by the protective effect expression of antigens RTI class I encoded by the major
of this immunization against pulmonary and liver metastases histocompatibility complex (MHC) could also be involved in
of tumours induced by the s.c. injection of S4T, a subline this newly expressed immunogenicity. The non expression of
isolated from the RMS 9-4/0 parental line. These CZT- these structures at the surface of the tumour cells (reviewed
resistant clonogenic variants (in vitro-selected) had lost their by Goodenow et al., 1985) or the abnormality of the balance
tumorigenicity in the immunocompetent but not in the between the expression of the two major components, as
immunodeficient rat, showing that these cells had acquired related by Katzav et al. (1985) could be closely related to
immunogenicity. Normal adult rats were immunized with their tumorigenicities and their metastatic abilities.
these cells and subsequently grafted with the parental cell Experiments are in progress to elucidate if these cells
line RMS 9-4/0. We observed a reduction in lung metastatic diversely express these RTI class I antigens.
invasion, suggesting that CZT-resistant clonogenic cells share To the effectors of the immune system such as NK
a common antigenicity with cells which are antecedents of lymphocytes and activated macrophages selected cells
the lung metastases of the RMS 9-4/0 tumour and of the appeared to be close to normal cells (self). Both tum- cell
liver and lung metastases of the S4T tumour. This new lines became progressively resistant to NK- and
characteristic could be linked to the CZT contact and not to macrophage-induced cytotoxicity. The loss of tumorigenicity
the cloning procedure itself, since these antigenic structures cannot be explained by this fact. Finally, using these
were not present on tumour cells selected only for procedures we have revealed two types of antigenicity. A
clonogenicity. However, we cannot exclude the hypothesis common antigen was present on R9 and C8 tum- cells,
that this new antigenicity in CZT-resistant cells has been which was responsible for a cross-linked protection
randomly obtained, by spontaneous mutation of the line demonstrated in nude mice by the Winn assay. Though we
more than by CZT-induced mutation. Untreated CFCs (C have shown that T cells transferred the immunological
lines) also lost their tumorigenicity in syngeneic immuno- protection, we have not succeeded with in vitro T-cell
competent rats, but when used as immunogens, they did not mediated cytotoxicity (negative results, not shown). A
prevent lung metastatic invasion. This phenotypic change is different antigen was present only on R9 cells, and not on
stable in the cell lineage and is probably related to the C8 cells. This latter antigenicity was present on metastatic
absence of host immunological selection during the selective cells and CZT-treated cloned cells. Moreover, these
pressure. We offer no explanation for this sudden loss of immunizing structures were also on CZT-resistant cells
tumorigenicity, or, better still, this sudden acquisition of selected in vivo. Concerning the fundamental aspects of the
immunogenicity. This event occurred in one colony (one cell) biology of metastases, this observation could be important in
derived from a clone subpopulation, itself non immunogenic, establishing a link between resistant parental cells and
as if this antigenicity was latent and its repression unstable. metastatic cells. In our studies, these two subpopulations had
On the other hand, the antigenic state seemed to be stable. common properties which led to their selection. Metastatic
The immunogenicity of R9 could be induced by CZT- dissemination of tumours involves cellular subpopulations
treatment. One elegant explanation, not yet proven, is that which could be more resistant to the chemotherapeutic drugs
repeated contact with CZT induces the amplification of than the cell populations of the primary lesion. An
antigenic structures which are present on tumour cells alternative could be that the metastatic cells could be more
capable of producing in vivo lung or liver metastases. The susceptible to the mutagenic effect of drugs, rendering these
high malignancy of tumours could be related to a complete cells subsequently more resistant. The evidence of a common
loss of antigenicity. However, Van Waes et al. (1986) antigenicity leads us to believe that the same cell can have
demonstrated the maintenance of one antigenic determinant the resistant and metastatic phenotypes and that cloning in
expressed on progressively more malignant variants derived semi-solid medium could isolate this cell.
from UV-induced tumours. Their data led to the conclusion We would like to thank V. Lascaux and Y. Rolland for their
that several structures exist on the poorly malignant, excellent technical help, Mrs P. Blanchin for secretarial assistance
parental line, some inducing immunological rejection and J. Jacobson for the improvement of the manuscript.TUM-CFCs FROM A RAT RHABDOMYOSARCOMA 13
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